Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 794078, 16 pages
http://dx.doi.org/10.1155/2014/794078
Review Article

Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis

1Institute of Cardiovascular Sciences, University of Manchester, Manchester Royal Infirmary, Manchester M13 9WL, UK
2Norfolk and Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK
3Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK

Received 24 August 2013; Accepted 18 December 2013; Published 2 March 2014

Academic Editors: J.-T. Cheng and G. Helft

Copyright © 2014 Chun Shing Kwok et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. N. Levine, E. R. Bates, J. C. Blankenship et al., “2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” Journal of the American College of Cardiology, vol. 58, no. 24, pp. e44–e122, 2011. View at Publisher · View at Google Scholar
  2. W. Wijns, P. Kolh, N. Danchin et al., “Guidelines on myocardial revascularization,” European Heart Journal, vol. 31, no. 20, pp. 2501–2555, 2010. View at Publisher · View at Google Scholar
  3. I. Iakovou, T. Schmidt, E. Bonizzoni et al., “Incidence, predictors and outcome of thrombosis after succesful implantation of drug-eluting stents,” The Journal of the American Medical Association, vol. 293, no. 17, pp. 2126–2130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. E. L. Eisenstein, K. J. Anstrom, D. F. Kong et al., “Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation,” The Journal of the American Medical Association, vol. 297, no. 2, pp. 159–168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. D.-W. Park, S.-W. Park, K.-H. Park et al., “Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up,” The American Journal of Cardiology, vol. 98, no. 3, pp. 352–356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. H.-C. Gwon, J.-Y. Hahn, K. W. Park et al., “Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents,” Circulation, vol. 125, no. 3, pp. 505–513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. B. K. Kim, M. K. Hong, D. H. Shin et al., “A new strategy for discontinuation of dual antiplatelet therapy,” Journal of the American College of Cardiology, vol. 60, no. 15, pp. 1340–1348, 2012. View at Publisher · View at Google Scholar
  8. S. J. Park, D. W. Park, Y. K. Kim et al., “Duration of dual antiplatelet therapy after implantation of drug-eluting stents,” The New England Journal of Medicine, vol. 362, pp. 1374–1382, 2010. View at Publisher · View at Google Scholar
  9. M. Valgimigli, G. Campo, M. Monti et al., “Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial,” Circulation, vol. 125, no. 16, pp. 2015–2026, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Hu and H. C. Wang, “AS-171 Duration of dual antiplatelet therapy and outcomes after left main percutaneous coronary intervention,” The American Journal of Cardiology, vol. 109, no. 7, pp. S85–S86, 2012. View at Publisher · View at Google Scholar
  11. S. Cassese, R. A. Byrne, T. Tadad et al., “Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a metaanalysis of randomized trials,” European Heart Journal, vol. 33, no. 24, pp. 3078–3087, 2012. View at Publisher · View at Google Scholar
  12. http://hiru.mcmaster.ca/hiru/HIRU_Hedges_EMBASE_Strategies.aspx and http://hiru.mcmaster.ca/hiru/HIRU_Hedges_MEDLINE_Strategies.aspx.
  13. J. P. Higgins and D. G. Altman, “Chapter 8: assessing risk of bias in included studies,” in Cochrane Handbook for Systematic Reviews of Interventions, J. P. Higgins and S. Green, Eds., pp. 187–241, Wiley-Blackwell, Hoboken, NJ, USA, 2008. View at Google Scholar
  14. J. P. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” PLOS Medicine, vol. 6, no. 7, Article ID e1000097. View at Publisher · View at Google Scholar
  16. http://www.prisma-statement.org/.
  17. M. Pfisterer, H. P. Brunner-La Rocca, P. T. Buser et al., “Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents,” Journal of the American College of Cardiology, vol. 48, no. 12, pp. 2584–2591, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Airoldi, A. Colombo, N. Morici et al., “Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment,” Circulation, vol. 116, no. 7, pp. 745–754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. R. Mehta, S. Yusuf, R. J. G. Peters et al., “Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study,” The Lancet, vol. 358, no. 9281, pp. 527–533, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. S. R. Steinhubl, P. B. Berger, J. Tift Mann III et al., “Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial,” The Journal of the American Medical Association, vol. 288, no. 19, pp. 2411–2420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Bernardi, J. Szarfer, G. Summay et al., “Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the randomized Argentine clopidogrel stent [RACS] trial),” The American Journal of Cardiology, vol. 99, no. 3, pp. 349–352, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. L. Grines, R. O. Bonow, D. E. Casey Jr. et al., “Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians,” Circulation, vol. 115, no. 6, pp. 813–818, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. J. Kirtane, A. Gupta, S. Iyengar et al., “Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies,” Circulation, vol. 119, no. 25, pp. 3198–3206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Räber, M. Magro, G. G. Stefanini et al., “Very late coronary stent thrombosis of a newer-generation eerolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study,” Circulation, vol. 125, no. 9, pp. 1110–1121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. G. G. Stefanini, R. A. Byrne, P. W. Serruys et al., “Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials,” European Heart Journal, vol. 33, no. 10, pp. 1214–1222, 2012. View at Publisher · View at Google Scholar
  26. T. Palmerini, G. Biondi-Zoccai, D. D. Riva et al., “Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis,” The Lancet, vol. 379, no. 9824, pp. 1393–1402, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Zhang, L. Shen, L. Hu, and B. He, “Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis,” The Journal of Clinical Pharmacology, vol. 53, no. 3, pp. 345–351, 2013. View at Publisher · View at Google Scholar
  28. B. Ba, Y. T. Ma, Z. X. Yu et al., “Optimal duration of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis,” Chinese Journal of Evidence-Based Medicine, vol. 12, no. 5, pp. 577–582, 2012. View at Google Scholar
  29. M. Valgimigli, S.-J. Park, H.-S. Kim et al., “Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials,” International Journal of Cardiology, vol. 168, no. 3, pp. 2579–2587, 2013. View at Publisher · View at Google Scholar
  30. T. Zhang, L. Shen, L. Hu et al., “Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis,” The Journal of Clinical Pharmacology, vol. 53, no. 3, pp. 345–351, 2013. View at Publisher · View at Google Scholar
  31. M. Valgimigli, M. Borghesi, M. Tebaldi et al., “Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY),” European Heart Journal, vol. 34, no. 12, pp. 909–919, 2013. View at Publisher · View at Google Scholar
  32. J. Yim, J. Petrofsky, L. Berk et al., “Differences in endothelial function between Korean-Asians and Caucasians,” Medical Science Monitor, vol. 18, no. 6, pp. CR337–CR343, 2012. View at Publisher · View at Google Scholar
  33. J. M. Lee, S. Park, D.-J. Shin et al., “Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans,” The American Journal of Cardiology, vol. 104, no. 1, pp. 46–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. R. A. Byrne, S. Schulz, J. Mehilli et al., “Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the intracoronary stenting and antithrombotic regimen: safety and efficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) study,” American Heart Journal, vol. 157, no. 4, pp. 620.e2–624.e2, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Mauri, D. J. Kereiakes, S.-L. Normand et al., “Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions,” American Heart Journal, vol. 160, no. 6, pp. 1035.e1–1041.e1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Feres, R. A. Costa, and A. Abizaid, “Optimized duration of clopidogrel therapy following treatment with the endeavorzotarolimus-eluting stents in the real-world clinical practice (OPTIMIZE) trial: rationale, design and preliminary results of a large-scale, randomized, multicenter study,” Journal of the American College of Cardiology, vol. 57, no. 14, supplement 1, E1729 pages, 2011. View at Publisher · View at Google Scholar
  37. G. Helft, C. Le Feuvre, J. L. Georges et al., “Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial,” Trials, vol. 14, article 56, 2013. View at Publisher · View at Google Scholar